Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment

Table 2 Univariate and multivariate analysis with respect to overall survival in 40 patients with eribulin chemotherapy for locally advanced or metastatic breast cancer

Parameters	Univariate analysis			Multivariate analysis
Parameters	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age at chemotherapy
≤ 63 vs. > 63	0.619	0.219–1.748	0.365
Degree of progress
Locally advanced vs. visceral metastases	2.441	0.549–10.854	0.241
Stage
IIIC or IV vs. recurrence	1.715	0.475–6.195	0.411
ER
Positive vs. negative	0.614	0.221–1.707	0.350
PgR
Positive vs. negative	0.699	0.239–2.049	0.514
HER2
Positive vs. negative	0.042	0.000–63.843	0.396
Ki67
≤ 14% vs. > 14%	0.634	0.227–1.769	0.384
Nuclear grade
1, 2 vs. 3	1.727	0.614–4.857	0.300
Objective response rate
ORR vs. non-ORR	0.160	0.043–0.593	0.006	0.065	0.011–0.388	0.003
TILs
High vs. low	0.535	0.192–1.486	0.230
Progression
Progression due to pre-existing lesions and high-TILs vs. others	0.221	0.062–0.787	0.020	0.105	0.021–0.532	0.006

ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor, ORR objective response rate, TILs tumor-infiltrating lymphocytes, CI confidence interval

ISSN: 1479-5876